Navigation Links
NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
Date:6/10/2009

p>

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL, TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV], and ACTIQ(R) (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements pro
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
2. Courage Center Is First in Midwest to Offer Innovative Treatment for Movement Disorders
3. BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights
4. Health Plans and IROs Can Work Together to Determine Proper Care for Eating Disorders
5. Heavy Periods May Be Due to a Clotting Disorder
6. Body and Weight Checking May Signify an Eating Disorder
7. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
8. Experts reach consensus on diagnosis and treatment of bleeding disorders in women
9. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
10. Hopkins study: When adult patients have anxiety disorder, their children need help too
11. ADHD Treatment Guide: How to Safely, Effectively Use Medications and Non-Drug Therapies to Treat Attention Deficit Disorder

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)... HAPPYneuron,s most popular and addictive...and iPod Touch. , Mountai...n,s most popular and addictive game, SplitWords, i...t Words is designed to help banish that ,tip of th...Phone brain game challenges the brain by encourag...
(Date:11/21/2009)... Linwood Group ask whether there is a sec...red? , London, UK (PRWEB)...th up to one in three of the adult UK population d...ing alcohol-related liver disease*, it is hardly a...habilitation programmes and residential centres fo...
(Date:11/20/2009)...HINGTON, Nov. 20 The A... to modify health care reform legislation released...a health insurance individual coverage mandate. Th... mandate will minimize adverse selection stemming ...ribed by the bill. ,, "The individual mandate l...
(Date:11/20/2009)... Senators and Congressmen in Competitive ... Health Care Vote , Washi...d congressmen running for re-election next year in...Charlie Cook, may come to regret voting for House ...ording to a breaking Zogby International/ O’...
(Date:11/20/2009).... LOUIS, Nov. 20 Cente... it will present at the Bank of America Merrill Ly...3, 2009, at the Crowne Plaza Hotel Times Square in...ay, December 2nd at 8:30 a.m. Eastern Time. Invest..., audio webcast of Centene,s presentation at: htt...
Breaking Medicine News(10 mins):Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3
... Applicants for Social Security Di...y; Allsup Answers Common Benefits Questions , ..., 2008 -- People who find themselves with a mental... about a person’s life changes, the past sti...
... Central Bucks Specialists, a lead...s MxSecure, Inc., the nation's leading provid... clinics, as their outsourced medical transcriptio...n's leading provider of medical transcription...
...ne of few trials to recruit large percentage of Af...ipants, PORTLAND, Ore., July 8 Keeping a food di... a study from Kaiser Permanente,s Center,for Healt...ssue of the American Journal of Preventive Medicin...
...ILLS, Calif., July 7 "For several months,senior l...orking on a,settlement agreement with the Californ...ure to all issues relating to previous rescissions...,review our proposal., Following are the key elem...
...uly 7 Ventas, Inc. (NYSE: VTR ),("Ventas" or the... 2008,second quarter earnings release after the cl...ence call to discuss those earnings will be held o...any,s website at http://www.ventasreit.com or at...
... Ill., July 7 The University HealthSystem,Consort... newly created,position of Chief Learning Officer....e in academic internal medicine and comes to UHC f...ingleton was the Petersdorf Scholar in Residence a...
Other Medicine News:Health News:Past Earnings Play Role in Determining SSDI Benefits 2Health News:Past Earnings Play Role in Determining SSDI Benefits 3Health News:Past Earnings Play Role in Determining SSDI Benefits 4Health News:Past Earnings Play Role in Determining SSDI Benefits 5Health News:Central Bucks Specialists, a Cardiology and Gastroenterology Multi-location Clinic, Selects MxSecure, Inc., Provider of Medical Transcription Services, as their Transcription Provider. 2Health News:Central Bucks Specialists, a Cardiology and Gastroenterology Multi-location Clinic, Selects MxSecure, Inc., Provider of Medical Transcription Services, as their Transcription Provider. 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 2Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 3Health News:Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss 4Health News:Anthem Blue Cross Statement on Settlement Discussions with the California Department of Managed Health Care 2Health News:University HealthSystem Consortium Names Susan K. Pingleton, MD, as Its Chief Learning Officer 2
(Date:11/19/2009)...an, Nov. 19 /PRNewswire-Asia/ -- ScinoPharm, a lea...edients (APIs), announced that its,Tainan facility...tion from,SafeBridge(R) Consultants, Inc. The Cert...ficiency in the safe handling of potent active,pha...cific laboratories and,production areas used for t...
(Date:11/19/2009)..., Nov. 19 The D e al ...f its Most Admired Corporate Dealmakers for the se...as its Most Admired Dealmaker in pharma/biotech fo... and divestitures since January 2006. ,, Over t...ortfolio with a focus on high-growth, innovation-d...
(Date:11/19/2009)...ational Internet Week of Action ,, SILVER SPRI...S. Food and Drug Administration today completed a ...d the International Internet Week of Action (IIWA)...al products. ,, (Logo: http://www.newscom.com/...ffort, the FDA,s Office of Criminal Investigations...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 1CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 3BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 1BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday July 30 at 5 3A00 p m ET 2823 3A00 CET 29 50515 2Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 1Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 2Air Force Chief Master Sergeant Rod McKinley 28U S Air Force Retired 29 Joins MicroTech as Vice President of Strategic Partnerships 12870 3
...um: The Takeda Oncology,Company today reported upd...ed Phase III clinical trials of VELCADE based comb...-eligible patients with previously untreated,multi...val (PFS) was observed,in one study comparing VELC...mycin and dexamethasone (VAD), as well as in anoth...
...sts that ofatumumab has activity in heavily pre-tr... , , , PHILADELPHIA, Dec. 8 GlaxoSmithKli... positive results from a pivotal trial pre-planned...he treatment of refractory chronic lymphocytic leu... of ofatumumab for heavily pre-treated patients wi...
Other Medicine Technology:Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9
...pose agarose, has been developed for analytical an... separation of high molecular weight DNA [pulsed-f...high gel strength agarose ( 1800 g/cm2, 1%). T...trations of agarose in electrophoretic gels. The a...
Agarose, high gel strength, Molecular Biology Grade
UltraClean™ Forensic Agarose
...se 1000 is specifically formulated for high resolu...This standard melting temperature agarose can reso...ce in size. UltraPure™ Agarose 1000 gels ex...nd improved clarity for enhanced visibility of fra...
Medicine Products: